Global Smoking cessation and nicotine de-addiction market is projected to register 27.1% CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:
Global Smoking Cessation and Nicotine De-Addiction Market-By Product Type (with nicotine and without Nicotine), Treatment Type (Pharmacological, Therapies and Others) Distribution Channel (Online, Offline), End-User (Generation Z, Millennials, Generation X and Silent Generation), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Japan, China, South Korea, India, Australia and New Zealand, Tawian, Hong-Kong, Singapore, Thailand, Malaysia, Indonesia, Philippines, Brazil, Argentina, UAE, Saudi Arabia, Egypt, Israel, South Africa and many others)-Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the global smoking cessation and nicotine de-addiction market:

• Growing adoption of e-cigarettes is expected to fuel the growth of the market
• Growing awareness among population owing to increasing diseases from smoking

Market Players:

The key players of global smoking cessation and nicotine de-addiction market are:

• Cipla Inc.
• Johnson & Johnson Services, Inc
• Takeda Consumer Healthcare Company Limited
• Alkalon A/S
• 22nd Century Group, Inc.
• GlaxoSmithKline plc.
• Imperial Brands
• Japan Tobacco Inc.
• British American Tobacco
• Perrigo Company plc
• Fertin Pharma
• Cambrex Corporation
• Dr. Reddy’s Laboratories Ltd.
• Pfizer Inc.
• Strides Pharma Science Limited